Literature DB >> 22866117

Evaluation of intraoperative and postoperative complications related to lymphadenectomy in ovarian cancer patients.

Leszek Jaroslaw Gmyrek1, Joanna Jonska-Gmyrek, Piotr Sobiczewski, Grzegorz Panek, Mariusz Bidzinski.   

Abstract

Assessment of the regional lymph node status is an integral part of diagnostics for ovarian cancer patients. Due to the risk of complications, lymphadenectomy for ovarian cancer patients, as a routine treatment procedure, is still a subject of controversy. Therefore, the present study aimed to evaluate the frequency and nature of intraoperative and postoperative complications in ovarian cancer patients treated with surgery. In addition, a comparison of the frequency and nature of surgical complications between patients who underwent lymphadenectomy and those who did not was carried out. A retrospective analysis of 211 consecutive ovarian cancer patients treated with surgery with pelvic and aortic lymphadenectomy (group I), and 258 ovarian cancer patients treated with surgery but without lymphadenectomy (group II) was carried out. All of the patients were treated with complementary chemotherapy. The frequency and nature of the intraoperative and postoperative complications were determined. The most frequent intraoperative complications in the two groups were haemorrhage, urinary system damage and digestive tract damage. The difference in the frequency and nature between the groups was not statistically significant (p=0.683). The most frequent postoperative complications were haemorrhage, intestinal junction dehiscence, eventrations, wound dehiscence, anaemia, wound healing complications and intestinal fistulas. Haemorrhage, eventrations and wound healing complications were more frequent in group I. The difference was statistically significant (p=0.002). Due to postoperative complications, reoperative procedures were necessary in two women in group II (0.78) and in 15 women (7.11%) in group I. The difference was statistically significant (p=0.000). In conclusion, the most frequent intraoperative complications were haemorrhage, urinary system damage and digestive tract damage. The frequency of complication was found to be similar in the two groups. A statistically significant higher rate of postoperative complications, such as haemorrhage, eventrations and wound healing complications was confirmed in the lymphadenectomy group.

Entities:  

Year:  2011        PMID: 22866117      PMCID: PMC3410484          DOI: 10.3892/ol.2011.281

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  17 in total

Review 1.  The surgical management of ovarian cancer.

Authors:  J F Stratton; J A Tidy; M E Paterson
Journal:  Cancer Treat Rev       Date:  2001-04       Impact factor: 12.111

2.  Systematic lymphadenectomy in advanced epithelial ovarian cancer: two decades of uncertainty resolved.

Authors:  Setsuko K Chambers
Journal:  J Natl Cancer Inst       Date:  2005-04-20       Impact factor: 13.506

3.  Ovarian cancer stage IIIC. Consequences of treatment level on overall and progression-free survival.

Authors:  H Oksefjell; B Sandstad; C Trope
Journal:  Eur J Gynaecol Oncol       Date:  2006       Impact factor: 0.196

4.  Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial.

Authors:  Pierluigi Benedetti Panici; Angelo Maggioni; Neville Hacker; Fabio Landoni; Sven Ackermann; Elio Campagnutta; Karl Tamussino; Raimund Winter; Antonio Pellegrino; Stefano Greggi; Roberto Angioli; Natalina Manci; Giovanni Scambia; Tiziana Dell'Anna; Roldano Fossati; Irene Floriani; Rita S Rossi; Roberto Grassi; Giuseppe Favalli; Francesco Raspagliesi; Diana Giannarelli; Luca Martella; Costantino Mangioni
Journal:  J Natl Cancer Inst       Date:  2005-04-20       Impact factor: 13.506

5.  Role of lymphadenectomy in the management of grossly apparent advanced stage epithelial ovarian cancer.

Authors:  Giovanni D Aletti; Sean Dowdy; Karl C Podratz; William A Cliby
Journal:  Am J Obstet Gynecol       Date:  2006-12       Impact factor: 8.661

Review 6.  Primary surgery for ovarian cancer.

Authors:  C Tropé; J Kaern
Journal:  Eur J Surg Oncol       Date:  2006-05-04       Impact factor: 4.424

7.  Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO).

Authors:  Andreas du Bois; Alexander Reuss; Eric Pujade-Lauraine; Philipp Harter; Isabelle Ray-Coquard; Jacobus Pfisterer
Journal:  Cancer       Date:  2009-03-15       Impact factor: 6.860

Review 8.  Update on lymphadenectomy in early and advanced ovarian cancer.

Authors:  Roberto Angioli; Francesco Plotti; Innocenza Palaia; Marco Calcagno; Roberto Montera; Ester Valentina Cafà; Maria Isabella Sereni; Pierluigi Benedetti Panici
Journal:  Curr Opin Obstet Gynecol       Date:  2008-02       Impact factor: 1.927

9.  Metastatic lymph node number in epithelial ovarian carcinoma: does it have any clinical significance?

Authors:  Ali Ayhan; Murat Gultekin; Polat Dursun; Nasuh Utku Dogan; Guldeniz Aksan; Suleyman Guven; Melih Velipasaoglu; Kunter Yuce
Journal:  Gynecol Oncol       Date:  2008-02       Impact factor: 5.482

10.  The potential therapeutic role of lymph node resection in epithelial ovarian cancer: a study of 13918 patients.

Authors:  J K Chan; R Urban; J M Hu; J Y Shin; A Husain; N N Teng; J S Berek; K Osann; D S Kapp
Journal:  Br J Cancer       Date:  2007-05-22       Impact factor: 7.640

View more
  1 in total

1.  Influence of bevacizumab on vaginal cuff evisceration eight months after ovarian cancer cytoreduction surgery: A case report.

Authors:  Amanda J Skwara; Russell J Schilder; Allison Zibelli; Norman G Rosenblum
Journal:  Gynecol Oncol Case Rep       Date:  2013-07-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.